24 March 2021 in Proceedings of the National Academy of Sciences
Significance: Understanding the working mechanism of a chemotherapy drug is a critical step toward achieving the patient-specific treatment strategy. Decitabine is an FDA-approved drug being used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Here, we employed an image-based screening platform to investigate the downstream factors of decitabine. We find that an RNA-binding protein Staufen1 (Stau1) is required for decitabine-mediated cancer cell death. We show that Stau1 stabilizes endogenous retrovirus RNAs induced by decitabine and transforms cells into the viral mimicry state. Indeed, MDS/AML patients with lower Stau1 expression show inferior response to decitabine. Our study unravels stabilization of key regulatory RNAs by Stau1 and suggests its potential use to predict decitabine-mediated therapy outcomes in clinics.
1 November 2024 in International Journal of Nanomedicine
The advent of acoustically responsive nanodrugs that are specifically optimized for sonodynamic therapy (SDT) is a novel approach for clinical applications. Examining the therapeutic applications of sono-responsive drug delivery systems, understanding their dynamic response to acoustic stimuli, and their crucial role in enhancing targeted drug delivery are intriguing issues for current cancer treatment. Specifically, the suggested review covers SDT, a modality that enhances the cytotoxic activity of specific compounds (sonosensitizers) using ultrasound (US). Notably, SDT offers significant advantages in cancer treatment by utilizing US energy to precisely target and activate sonosensitizers toward deep-seated malignant sites. The potential mechanisms underlying SDT involve the generation of radicals from sonosensitizers, physical disruption of cell membranes, and enhanced drug transport into cells via US-assisted sonoporation. In particular, SDT is emerging as a promising modality for noninvasive, site-directed elimination of solid tumors. Given the complexity and diversity of tumors, many studies have explored the integration of SDT with other treatments to enhance the overall efficacy. This trend has paved the way for SDT-based multimodal synergistic cancer therapies, including sonophototherapy, sonoimmunotherapy, and sonochemotherapy. Representative studies of these multimodal approaches are comprehensively presented, with a detailed discussion of their underlying mechanisms. Additionally, the application of audible sound waves in biological systems is explored, highlighting their potential to influence cellular processes and enhance therapeutic outcomes. Audible sound waves can modulate enzyme activities and affect cell behavior, providing novel avenues for the use of sound-based techniques in medical applications. This review highlights the current challenges and prospects in the development of SDT-based nanomedicines in this rapidly evolving research field. The anticipated growth of this SDT-based therapeutic approach promises to significantly improve the precision of cancer treatment.
8 March 2022 in Current Problems in Cancer
13 November 2025 in Clinical Cancer Research
Purpose: Targeting aberrant metabolism in tumors with alterations in genes encoding Krebs cycle enzymes, a central component of glucose metabolism, is a promising therapeutic strategy. These tumors rely on aerobic glycolysis and promote VEGF-dependent angiogenesis; furthermore, EGFR signaling enhances aerobic glycolysis. This phase II trial evaluated bevacizumab and erlotinib in patients with solid tumors harboring Krebs cycle gene mutations. Patients and Methods: Eligible patients had solid tumors bearing pathogenic mutations in fumarate hydratase (FH), isocitrate dehydrogenase 1/2, succinate dehydrogenase, or maleate dehydrogenase 2 and measurable disease per RECIST version 1.1 or Response Assessment in Neuro-Oncology 2.0 criteria. Participants received bevacizumab (10 mg/kg IV on day 1) and erlotinib (150 mg orally once daily) every 14 days until progression or unacceptable toxicity. The primary endpoint was the objective response rate (ORR); secondary endpoints were progression-free survival (PFS), overall survival, and safety. Results: From February to November 2023, 35 participants were enrolled: 19 with biliary tract cancer (54.3%), seven with brain tumors (20.0%), and five with FH-deficient renal cell carcinomas (FH-deficient RCC, 17.1%). ORR was 37.1% (one complete and 12 partial responses). The disease control rate was 85.7%. Subgroup ORR were 80.0% in FH-deficient RCC, 36.8% in biliary tract cancer, and 28.6% in brain tumors. At a median follow-up of 11.7 months, the median PFS was 8.3 months; median overall survival was not reached. No new safety signals were observed. Exploratory transcriptomic analyses revealed VEGF and immune pathway enrichment in patients with favorable PFS, whereas amino acid, fatty acid metabolism, and oxidative phosphorylation–related pathways were enriched in those with poor PFS. Conclusions: Bevacizumab plus erlotinib demonstrated promising efficacy in tumors with Krebs cycle gene mutations, warranting further investigation beyond FH-deficient RCC.
5 January 2026 in PLOS ONE
Objective: This study aimed to compare abdominopelvic computed tomography (APCT) image quality using low and high concentrations of a contrast agent in patients with cancer via a noninferiority design. Methods: This study prospectively included 99 patients with malignancies who underwent dual-source APCT following injection of 1.5 mL/kg of iohexol 270 (low-concentration group). The control group included patients who were retrospectively matched 1:1 based on weight, body mass index, and sex. These patients (high-concentration group) received 1.1 or 1.2 mL/kg of iohexol 350, reconstructed at two tube voltages (80 kVp and 80/Sn150 kVp). The noninferiority margins were set at −0.21 for overall image quality. Two radiologists blindly and independently analyzed the subjective and objective image quality of matching focal lesions. Results: A total of 198 patients with 102 focal lesions (44 liver lesions, 58 renal lesions) were assessed. The total iodine amount was slightly higher in the low-concentration group than in the high-concentration group without significant differences (24580.0 ± 3745.6 vs. 24190.2 ± 3954.3 mg I/mL; p = 0.051). Overall image quality did not differ significantly between the groups (2.6 ± 0.5 vs. 2.6 ± 0.5 on 80 kVp; p = 0.484; 3.4 ± 0.5 vs. 3.4 ± 0.6 on 80/Sn 150 kVp, p = 0.891). Margin sharpness and conspicuity also showed no significant differences between the low- and high-concentration groups at 80 kVp ( p = 0.890, 0.103) and 80/Sn 150 kVp images ( p = 0.278, 0.369). Liver attenuation was slightly higher in the low-concentration than in the high-concentration group (80 kVp, 127.3 ± 16.8 vs. 122.4 ± 13.0, p = 0.013; 80 kVp/Sn 150 kVp, 108.2 ± 13.3 vs. 104.5 ± 10.9, p = 0.025). No major or minor adverse reactions occurred during or immediately after contrast agent injection in either group. Five patients in the low-concentration group experienced below-average vascular pain. Conclusions: The low-concentration group offered noninferior overall image quality compared to the high-concentration group among patients with cancer.
31 March 2017 in Korean Journal of Construction Engineering and Management
Seamless Superimposition Technique of Virtual Objects for AR System of Excavator Based on Image Processing Augmented Reality;Image Processing;Superimposition;Extrinsic Calibration;Excavator; Recently, with having a great interest of the general public for the AR (Augmented Reality) technology, there have been lots of study to improve efficiency of a construction equipment with applying the AR technology to a construction equipment. The clear extrinsic calibration is essential to applying AR technology at the construction site without any error which came from superimposition between 'Real world' and 'Virtual world'. However, on the construction site, the clear extrinsic calibration is not possible, because of lack of time and budget for the specific survey, also, the huge error of the outdoor tracking system such as gyro, GPS system and so on. In this study, we do research about seamless superposition with unclear extrinsic calibration and the image process method for making AR navigator operating in the excavator. Based on this study, we figure that we can fully develop the AR navigator for the excavator. Furthermore, thereby operating AR navigator at many construction sites, we expect that the efficiency of the excavator will be improved. In addition, we can develop AR navigator for not only a excavator but all about construction equipment.